STERIS plc (NYSE: STE) is a healthcare and life sciences company that provides infection prevention products and sterilization services to hospitals, surgery centers, and pharmaceutical and medical device manufacturers. Revenue comes from three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, mixing recurring consumable and service revenue with capital equipment sales. The Healthcare segment sells cleaning chemistries, sterility assurance products, surgical tables, automated endoscope reprocessors, and repair services to sterile processing departments and procedural centers worldwide. The AST segment provides contract microbial reduction services for medical devices, using cobalt-60 and ethylene oxide (EO) as key inputs. As of March 31, 2025, the company held 607 U.S. patents and 2,315 patents in other jurisdictions, and carried a debt-to-total-capital ratio of 23.6%. Operating cash flow was $1,148.1 million and free cash flow was $787.2 million in fiscal 2025 (year ended March 31, 2025). STERIS has paid and increased quarterly dividends each consecutive year since 2005, reaching $0.57 per share in fiscal 2025.

Revenue model

Revenue is generated through three streams: consumable product sales (detergents, endoscopy accessories, barrier products, instruments), service contracts (equipment installation, maintenance, instrument repair, outsourced reprocessing, contract sterilization), and capital equipment sales (sterilizers, surgical tables, automated endoscope reprocessors). The consumable and service portions provide recurring revenue; capital equipment is transactional. No single Healthcare segment customer represented more than 10% of that segment's revenues for the year ended March 31, 2025.

Products and services

Healthcare segment: cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, endoscopy accessories, surgical tables, lights, washers, sterilizers, instrument and scope repair, outsourced sterile processing, OR integration and connectivity solutions. AST segment: contract sterilization and microbial reduction of medical devices using cobalt-60 irradiation and ethylene oxide. Life Sciences segment: products and services supporting pharmaceutical and medical device manufacturing sterility requirements.

Customers and end markets

Primary customers are hospitals, surgery centers, endoscopy suites, and sterile processing departments in the Healthcare segment. AST and Life Sciences segments serve medical device manufacturers and pharmaceutical companies requiring contract sterilization and laboratory testing. No single Healthcare customer exceeded 10% of segment revenues in fiscal 2025 (year ended March 31, 2025).

Value-chain role

STERIS sits between raw material suppliers (stainless steel, organic and inorganic chemicals, cobalt-60, EO, plastic components, electronics) and end-use healthcare and life sciences customers. It manufactures capital equipment and consumables, operates contract sterilization facilities, and provides on-site and off-site repair and reprocessing services. Single-source dependencies exist for cobalt-60 and EO in certain regions.

Geographic exposure

Products are sold and services are provided worldwide. Manufacturing and assembly occur in multiple countries. Patent holdings span 607 U.S. patents and 2,315 patents in other jurisdictions as of March 31, 2025, indicating broad international commercial presence. Specific country-level revenue breakdowns are not provided in the excerpts.

Source: SEC 10-K, filed 2025-05-29

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: Medtronic PLC Trinity Biotech PLC